Arthneeti
IC

IOL Chemicals & Pharmaceuticals Ltd

Q3 FY26Pharmaceuticals & Biotechnology

IOL Chemicals & Pharmaceuticals Ltd Q3 FY26 Results & Concall Highlights: Revenue, Margins & Order Book

Q3 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹170
Market cap₹4.8K Cr
P/E32.8
Updated23 Aug 2026
Read4 min read

The short version

The company expects a minimum 10% to 15% growth in top line (sales/revenue) in the coming year (FY '27). Company expects 10% to 15% growth in top line for FY '27.

From IOL Chemicals & Pharmaceuticals Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • The company expects a minimum 10% to 15% growth in top line (sales/revenue) in the coming year (FY '27).
  • Bottom-line growth is anticipated between 15% to 20%.
  • The focus is on increasing exports, especially of pharmaceutical products, including efforts to boost the non-ibuprofen (non-ibu) API share.
  • Capacity utilization is high for pharma (above 90%), except paracetamol which is expanding; chemicals utilization is near 200%.
  • The paracetamol segment is expected to be a key growth driver, alongside metformin and the shift of non-ibu domestic sales to regulated markets.
  • New capacities are being planned, with ongoing capex of around INR 150-200 crores annually.
  • The company is targeting a balanced product mix aiming for 60% revenue from API and 40% from chemicals in next 2 years, with growth driven by both ibuprofen and non-ibuprofen APIs.
  • Revenue guidance for Q4 is INR 600 crores with improved margins.

Profitability & Margins

See what IOL Chemicals & Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • FY '26 capex budget was around INR 150 crores; actual expected slightly lower (~INR 130-135 crores).
  • Approximately 60% of FY '26 capex directed towards growth, and 40% towards infrastructure development and automation.
  • For FY '27, the company plans a similar level of capex (~INR 150-200 crores), though final plans are yet to be finalized.
  • Capex aims to support increased capacity, particularly expanding key products like paracetamol and non-ibuprofen APIs.
  • New land acquisition is in process with environmental clearances secured; pending approvals with national highway authorities; intended for setting up additional plants.
  • Focus on enhancing capacity utilization and broadening product portfolio with ongoing R&D efforts for new molecules in API and chemical segments.

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

5x potential
1Accretion Pha.
Rev 1Mar 2
2OneSource Specialty Pharma Ltd
Rev 1Mar 3
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 2Mar 1
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what IOL Chemicals & Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The transcript provided does not explicitly mention details regarding the current or expected order book or pending orders for IOL Chemicals and Pharmaceuticals Limited. However, some relevant points from the discussion related to business momentum and growth include: - The company reported revenue growth and strong capacity utilization (ibuprofen plant running over 90% capacity). - They expect to achieve revenue of around INR600 crores in Q4. - Focus on expanding products, increasing non-ibuprofen API share, and regulated market exports. - Capex plans of approximately INR150-200 crores aimed at growth and capacity expansion. - Ongoing R&D efforts and product pipeline expansion to strengthen future product offerings. - Emphasis on customer relationships and disciplined execution supporting sustained order flow. For specifics on the order book or pending orders, the transcript does not provide direct information. You may contact their IR team for detailed order book data.

IOL Chemicals & Pharmaceuticals Ltd — Quarterly revenue & net profit

Revenue Net profit
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹619 Cr, net profit ₹53 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What IOL Chemicals & Pharmaceuticals Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • OneSource Specialty Pharma Ltd (Q3 FY26)

    OneSource Specialty Pharma is aggressively investing in capacity expansion with over INR 700 crores (approximately $100 million) planned for flagship site…

  • Mankind Pharma Ltd (Q3 FY26)

    Overall domestic prescription business growth for Q3 was 9%+ and 8.2% for 9 months (excluding OTC), indicating steady growth. Key concall takeaways from…

  • Gland Pharma (Q3 FY26)

    Investments of INR 2,000 crores over next 5 years, including Brownfield expansions, BFS lines, and ophthalmic lines, to enhance capacity and drive volume/value…

  • Shilpa Medicare Ltd (Q3 FY26)

    Formulation business growing robustly, with 104% quarter-on-quarter growth excluding licensing income. Key concall takeaways from Shilpa Medicare's Q3 FY26…

Compare:vs Sun Pharmaceutical Industries Ltdvs Divis Laboratories Ltdvs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were IOL Chemicals & Pharmaceuticals Ltd Q3 FY26 results?

The company expects a minimum 10% to 15% growth in top line (sales/revenue) in the coming year (FY '27). Company expects 10% to 15% growth in top line for FY '27.

What is IOL Chemicals & Pharmaceuticals Ltd share price analysis?

IOL Chemicals & Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 32.8 with a market cap of ₹4,797 Cr. Investors should review the full earnings analysis for detailed insights.

Is IOL Chemicals & Pharmaceuticals Ltd planning capital expenditure?

FY '26 capex budget was around INR 150 crores; actual expected slightly lower (~INR 130-135 crores).

Keep IOL Chemicals & Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.